Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18

Canaccord Genuity analyst Whitney Ijem has initiated coverage on Quoin Pharmaceuticals (NASDAQ: QNRX) with a Buy rating. The firm has set a price target of $18 for the stock.